Gregory T. (Greg) Knipp
MS Pharmaceutical Chemistry, 1995, The University of Kansas
PhD, Pharmaceutical Chemistry, 1997, The University of Kansas
Post-Doctoral Fellow, Department of Integrative and Molecular Physiology, The University of Kansas - Medical Center 1997-1999
Dr. Knipp's research interests include the molecular and functional characterization of oligopeptide transporters, where he has been focusing on the characterization of the human Peptide/Histidine Transporter 1 isoform in human intestinal and blood brain barrier cell lines. He is interested in determining the effect of xenobiotics, particularly delineating the roles of DEHP and Bisphenol A, on placental fatty acid homeostasis and fetal development.
He has also been interested in investigating the effects of processing induced dosage form variation on clinical performance utilizing in vitro and in vivo (porcine) models. His recent work has focused on the utilization of the porcine model for testing the pharmacokinetics of novel pediatric formulations developed within his laboratory.
IPPH 36300 Basic Pharmaceutics II
IPPH 45100 Industrial Practical Training
IPPH 58300 Advanced Biopharmaceutics
CHE 567E Fundamentals of Pharmaceutical Engineering
RESEARCH AND TEACHING GRANTS:
Jan. 2012-Dec. 2013 - The Dane O. Kildsig-Center for Pharmaceutical Processing Research, Research Grant, “PEG(5000)-cHSA: A Solubility Enhancing Excipient With Multiple Applications.”
Dec. 2011-Dec. 2013 - Bristol-Myers Squibb, (PI), Grant, “The Effect of Conformation on the Permeation of Oligopeptides.”
Oct. 2011-Sept. 2012 - Eli Lilly and Company, (PI), Grant, “Pharmacokinetic Studies on Hyperglycemic Agents in Immediate and Modified Release Formulations in Pigs.”
June 2011-May 2012 - 2011 Purdue Research Foundation Research Grant, (PI), Graduate Fellowship Support for Lori Karpes, “The Effects of DEHP Exposure on Fatty Acid Homeostasis Across the Immortalized Human Blood Brain Barrier Cell Line, hCMEC/D3.”
Mar. 2011-Dec. 2011 - National Institute of Pharmaceutical Technology Education, (Co-PI), “Reviewer Education in State of the Art Pharmaceutical Manufacturing Technology.”
Oct. 2010-Dec. 2011 - Eli Lilly and Company, (PI), Pilot Grant, “Pharmacokinetic Studies on Glipizide Immediate and Modified Release Formulations in Pigs.”
Sept. 2010-Present - The Indiana Clinical Translational Sciences Institute, (Co-PI), "Establishment of the Purdue Porcine Translational Pharmacology Core."
June 2010-May 2012 - The Indiana Clinical Translational Sciences Institute, (Co-PI), CBR/CTR Pilot Grant, "Engineering Multifunctional Micellar Nanoparticles to Overcome Drug Resistance in Multiple Myeloma."
Jan. 2009-Dec. 2011 - The Dane O. Kildsig Center for Pharmaceutical Processing Research, Research Grant, “Establishing the PigTurn Model Monitor Human Clinical Impact of Process Variation”.
R.P. Gala, C. Popescu, G.T. Knipp*, R.R. McCain, R.V. Ubale, R. Addo, T. Bhowmik, C.D. Kulczar, and M.J. D’Souza*, Physicochemical and Preclinical Evaluation of a Novel Buccal Measles Vaccine. AAPS PharmSciTech [Pediatric Drug Development and Dosage Form Theme Issue] 1-10 (EPub June 29, 2016; Shared: http://rdcu.be/ndT7).
J. Kim, Y.L. Jones, R. Wei, J. Myers, Y. Qi, G.T. Knipp, and W. Liu. Association between hTERT rs2736100 polymorphism and sensitivity to anti-cancer agents. Front. Genetics. 4 (Article 162):1-6 (2013).
W.J. Roth, C.B. Kissinger, R.R. McCain, B.R. Cooper, J.N. Marchant-Forde, R.C. Vreeman, S. Hannou, and G.T. Knipp. Assessment of Juvenile Pigs to Serve as Human Pediatric Surrogates for Preclinical Formulation Pharmacokinetic Testing. AAPS J. [Theme Issue: Challenges and Opportunities in Pediatric Drug Development] 15 (3):763-774 (2013; EPub: April 18, 2013).
Editorial: Perspectives on Pediatric Drug Development. Roth, WJ, Sage, DP, Kulczar, C, Liu, W, and Knipp, GT. Revista Mexicana De Ciencias Farmaceuticas 2012; 43 (3):5-6.
Comparative Pharmacokinetic Studies of Immediate and Modified Release Formulations of Glipizide in Pigs and Dogs. Kulkarni, R, Yumibe, N, Wang, Z, Zhang, X, Tang, CC, Ruterbories, K, Cox, A, McCain, R, and Knipp, GT. J. Pharm. Sci. 2012; 101 (11): 4327-4336, 2012. Epub 19 August 2012.
The Effects of Intra-Laboratory Modifications to Media Composition and Cell Source on the Expression of Pharmaceutically Relevant Transporters and Metabolizing Genes in the Caco-2 Cell Line. Roth WJ, Lindley, DJ, Carl, SM, and Knipp, GT. J. Pharm. Sci. 11 July 2012; 101 (10): 3962-3978. Epub 11 July 2012.
The Effects of Media on Pharmaceutically Relevant Transporters in the Human HT-29 Adenocarcinoma Cell Line: Does Culture Media Need to be Controlled? Lindley, DJ, Roth, WJ, Carl, SM, and Knipp, GT. J. Pharm. Sci. 2012; 101 (4): 1616-1630.
Plasma Cortisol and Noradrenalin Concentrations in Pigs: Automated Sampling of Freely Moving Pigs Housed in the PigTurn® Versus Manually Sampled and Restrained Pigs. Marchant-Forde, JN, Matthews, DL, Poletto, R, McCain, RR, Mann, DD, McGraw, RT, Hampsch, J, Peters, S, Knipp, GT, and Kissinger, CB. Anim. Welfare 2012; 21: 197-205.
Assessing the Performance of Amorphous Solid Dispersions. Newman, A, Knipp, G, and Zografi, G. J. Pharm. Sci. 2012: 101: 1355–1377.
Summary of the national institute of child health and human development-best pharmaceuticals for children act pediatric formulation initiatives workshop-pediatric biopharmaceutics classification system working group. Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Members of the BCS Task Force. Clin Ther. 2012 Nov;34(11):S11-24. doi:10.1016/j.clinthera.2012.09.014.
"ABC and SLC Transporter Expression and Proton Oligopeptide Transporter (POT) Mediated Permeation across the Human Blood-Brain Barrier Cell Line, hCMEC/D3". Carl SM, Lindley DJ, Das D, Couraud PO, Weksler BB, Romero I, Mowery SA, Knipp GT. Mol Pharm. 2012 Nov 6. [Epub ahead of print] No abstract available.
The Evaluation of Peptide/Histidine Transporter 1 (PHT1) Function: Uptake Kinetics Utilizing a COS-7 Stably Transfected Cell Line. Lindley DJ, Carl SM, Mowery S, Knipp GT. Revista Mexicana De Ciencia Farmaceuticas, octubre-diciembre 2011; 42(4);57-65.
ABC and SLC transporter expression and pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I, Mowery SA, Knipp GT. Mol Pharm. 2010 Aug 2;7(4):1057-68.
The effects of excipients on transporter mediated absorption. Goole J, Lindley DJ, Roth W, Carl SM, Amighi K, Kauffmann JM, Knipp GT. Int J Pharm. 2010 Jun 30;393(1-2):17-31. Epub 2010 Apr 24.
1. D.J. Lindley, S.M. Carl, D.R. Herrera-Ruiz, L.-F. Pan, L.B. Ward, J.M.E. Goole, O.S. Gudmundsson, and G.T. Knipp. Chapter 18: Drug Transporters and Their Role in Absorption and Disposition of Peptides and Peptide Based Pharmaceuticals. In Oral Bioavailability: Basic Principles, Advanced Concepts and Application. Eds. M. Hu and X. Li. In the Wiley Series on Drug Discovery and Development, Series Ed. B. Wang, John Wiley & Sons, New York, NY. pp. 291-308 (2011).
2. S.M. Carl, D.J. Lindley, G.T. Knipp, K.R. Morris, E. Oliver, G.W. Becker and R.A. Arnold. Biotechnology Drug Product Development. In Pharmaceutical Manufacturing Handbook, Editor S.H. Gad, John Wiley & Sons, New York, NY, pp. 1-32 (2008). [DOI: 10.1002/9780470259818.ch1; Republished in a Wiley Special Edition Series “Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing.” DOI: 10.1002/9780470571224.pse340 1-26 (2010)]
3. E. Oliver, S.M. Carl, K.R. Morris, G.W. Becker and G.T. Knipp. Regulatory Considerations in the Approval of Follow-On Protein Drug Products. In Pharmaceutical Manufacturing Handbook, Editor S.H. Gad, John Wiley & Sons, New York, NY, pp. 33-57 (2008). [DOI: 10.1002/9780470259818.ch2; Republished in a Wiley Special Edition Series entitled “Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing.” 1–32 (2010)]
4. S.M. Carl, D.J. Lindley, G.T. Knipp, K.R. Morris, E. Oliver, G.W. Becker and R.A. Arnold, Biotechnology Drug Product Development. In Pharmaceutical Manufacturing Handbook, Editor S.H. Gad, John Wiley & Sons, New York, NY, pp. 1-32 (2008).
5. E. Oliver, S.M. Carl, K.R. Morris, G.W. Becker and G.T. Knipp. Regulatory Considerations in the Approval of Follow On Protein Drug Products. In Pharmaceutical Manufacturing Handbook, Editor S.H. Gad, John Wiley & Sons, New York, NY, pp. 33-57 (2008).
6. R.K. Bhardwaj, D.R. Herrera-Ruiz, Y. Xu, S.M. Carl, T.J. Cook, N. Vorsa, and G.T. Knipp. Chapter 7: Intestinal Transporters in Drug Absorption. In Biopharmaceutics Applications in Drug Development. Editors R. Krishna and L. Yu, Kluwer Press, NY, pp. 175-261 (2008).
Edited Textbook Chapters
Martin’s Physical Pharmacy and Pharmaceutical Sciences, Fifth Edition. Editor Patrick J. Sinko. Lippincott, Williams & Wilkins, Baltimore, MD, (2006).
1. G.T. Knipp and K.R. Morris, Chapter 2: States of Matter.
2. H. Morelos, D. Herrera-Ruiz, and G.T. Knipp, Chapter 3: Thermodynamics.
3. G.T. Knipp, H. Morelos and D. Herrera-Ruiz, Chapter 4: Physical Properties of Drug Molecules.
- N. Yumibe, R. Kulkarni, Z. Wang, X. Zhang, K. Ruterbories, A. Cox, R. Ajamie, C.C. Tang, G. Knipp, Robin McCain. Comparative Pharmacokinetic Studies of Immediate and Modified Release Formulations of Glipizide in Pigs and Dogs. 2011 AAPS Indiana/Ohio Discussion Group-Pharma Industry Challenges/Perspectives Symposium, Indianapolis, IN. (2011).
- W.J. Roth, C.B. Kissinger, S. Hannou, B.R. Cooper, R.R. McCain, R. Vreeman, and G.T. Knipp. Development and Testing of Novel Pediatric Formulation of Rifampicin for the Treatment of Tuberculosis (TB) in Infants and Young Children. 2011 AAPS Indiana/Ohio Discussion Group-Pharma Industry Challenges/Perspectives Symposium, Indianapolis, IN. (2011). Best Poster Award